Table 5.
Annual expenditure from 2016 to 2023 stratified by ATMP category (n = 6 ATMPs)
| Year | ATMP expenditure in million € | Incidence on total SSN expenditure (‰) | CAR-T | Non-CAR-T | ||
|---|---|---|---|---|---|---|
| Ex vivo gene therapy (mln €) | Tissue-engineered therapy (mln €) | In vivo gene therapy (mln €) | Ex vivo gene therapy (mln €) | |||
| 2016 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2017 | 0.09 | 0 | 0 | 0.1 | 0 | 0 |
| 2018 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019 | 1.4 | 0.1 | 1.2 | 0.2 | 0 | 0 |
| 2020 | 16.7 | 0.7 | 16.7 | 0 | 0 | 0 |
| 2021 | 73.5 | 3.1 | 48.4 | 0.2 | 25 | 0 |
| 2022 | 86 | 3.4 | 70.6 | 0.2 | 15.3 | 0 |
| 2023 | 121.4 | 4.6 | 106.7 | 0.1 | 14.6 | 0 |
mln, million